1h Free Analyst Time
According to the recently published report, Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.Speak directly to the analyst to clarify any post sales queries you may have.
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate infection. Secreted glycoprotein G helps RSV escape antibody-dependent restriction of replication by acting as an antigen decoy and by modulating the activity of leukocytes bearing Fc gamma receptors.
The report outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Respiratory Syncytial Virus (RSV) Infections.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
- The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview
- Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Bavarian Nordic AS
- IDBiologics Inc
- Sigmovir Biosystems Inc
- Visterra Inc
- Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles
- MVA-BN RSV - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- respiratory syncytial virus (virus like particle) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RSV - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TRL-3D3 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VIS-RSV - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products
- Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones
- Featured News & Press Releases
- Nov 14, 2022: Chinese CDE grants IND clearance for Nuance’s RSV vaccine trial
- Jun 28, 2022: Bavarian Nordic announces grant of PRIME eligibility from the European Medicines Agency for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
- Apr 20, 2022: Bavarian Nordic announces initiation of a global phase 3 clinical trial of its RSV vaccine candidate in older adults
- Feb 22, 2022: Open Orphan : FDA breakthrough designation for Big Pharma RSV candidate
- Feb 14, 2022: Bavarian Nordic announces Breakthrough Therapy Designation for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
- Dec 06, 2021: Bavarian Nordic commits to initiating phase 3 trial of RSV vaccine candidate and to strengthening its capital base
- Sep 07, 2021: Open Orphan: Positive results from RSV Human Challenge Study
- Sep 01, 2021: Bavarian Nordic reports positive results from human challenge trial of its RSV vaccine candidate
- Aug 08, 2018: Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
- Mar 06, 2018: Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
- Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
- Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine
- Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
- Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV
- Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AstraZeneca Plc, 2022
- Pipeline by Bavarian Nordic AS, 2022
- Pipeline by IDBiologics Inc, 2022
- Pipeline by Sigmovir Biosystems Inc, 2022
- Pipeline by Visterra Inc, 2022
- Dormant Projects, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Bavarian Nordic AS
- IDBiologics Inc
- Sigmovir Biosystems Inc
- Visterra Inc
